Keyphrases
Adalimumab
7%
Adjusted Hazard Ratio
7%
Adult Atopic Dermatitis
5%
Adult Patients
6%
Adverse Events
5%
Area Index
8%
Asthma
6%
Atopic Dermatitis
63%
Biologic Therapy
7%
Biological Treatment
9%
Cardiovascular Risk
8%
Comorbidity
16%
Confidence Interval
35%
Denmark
18%
Drug Survival
7%
Hazard Ratio
10%
Healthcare Utilization
5%
Hidradenitis Suppurativa
7%
Incidence Rate
18%
Inflammatory Bowel Disease
9%
Ixekizumab
10%
Major Adverse Cardiovascular Events
5%
Meta-analysis
26%
Migraine
6%
Moderate-to-severe Psoriasis
29%
National Cohort Study
30%
Nationwide Registry
5%
Odds Ratio
10%
Patient Characteristics
5%
Placebo
5%
Population-based Cohort Study
12%
Psoriasis
100%
Psoriasis Area
7%
Psoriasis Disease
7%
Psoriasis Severity
12%
Psoriatic Arthritis
32%
Risk Factors
7%
Rosaceae
22%
Secukinumab
7%
Severity Index
8%
Systematic Meta-analysis
23%
Topical Corticosteroids
8%
Ustekinumab
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
Atopic Dermatitis
35%
Biological Product
19%
Cardiovascular Disease
8%
Clinical Trial
5%
Cohort Study
30%
Comorbidity
9%
Disease
12%
Inflammatory Bowel Disease
5%
Interleukin 17
7%
Ixekizumab
5%
Placebo
5%
Prevalence
14%
Psoriasis
68%
Psoriasis Vulgaris
10%
Psoriatic Arthritis
17%
Rosacea
5%
Secukinumab
7%
Suppurative Hidradenitis
5%
Topical Corticosteroid
8%
Ustekinumab
5%
Medicine and Dentistry
Atopic Dermatitis
36%
Biological Product
8%
Cardiovascular Disease
5%
Cardiovascular System
6%
Case-Control Study
5%
Cohort Analysis
29%
Cross Sectional Study
6%
Disease
13%
Hazard Ratio
10%
Ixekizumab
6%
Meta-Analysis
8%
Migraine
5%
Odds Ratio
6%
Prevalence
9%
Psoriasis
59%
Psoriasis Area and Severity Index
5%
Psoriasis Vulgaris
7%
Psoriatic Arthritis
13%
Rhinophyma
23%
Systematic Review
9%
Topical Corticosteroid
5%
